Zoetis Inc. (NYSE:ZTS) Receives $212.75 Consensus PT from Brokerages

Shares of Zoetis Inc. (NYSE:ZTS - Get Free Report) have been given an average recommendation of "Buy" by the ten ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $212.75.

ZTS has been the topic of several recent research reports. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler raised their target price on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Stifel Nicolaus decreased their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Finally, UBS Group dropped their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th.

Zoetis Stock Down 2.7%

NYSE:ZTS traded down $4.55 on Friday, hitting $164.27. The stock had a trading volume of 2,973,481 shares, compared to its average volume of 2,552,614. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis has a 52 week low of $139.70 and a 52 week high of $200.33. The business's fifty day moving average is $158.67 and its 200 day moving average is $163.83. The company has a market cap of $73.13 billion, a PE ratio of 30.03, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the previous year, the business posted $1.38 EPS. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. On average, equities research analysts expect that Zoetis will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.22%. Zoetis's payout ratio is 35.91%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president now owns 15,129 shares of the company's stock, valued at $2,571,930. This represents a 4.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zoetis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. purchased a new position in Zoetis in the 1st quarter valued at approximately $25,000. 1248 Management LLC purchased a new stake in Zoetis during the 1st quarter worth about $27,000. Rakuten Securities Inc. boosted its stake in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 166 shares during the period. Saudi Central Bank bought a new stake in shares of Zoetis during the first quarter valued at about $29,000. Finally, Navigoe LLC bought a new stake in shares of Zoetis during the fourth quarter valued at about $30,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.